Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
dc.contributor.author | Miguélez Palomo, Cristina | |
dc.contributor.author | Benazzouz, Abdelhamid | |
dc.contributor.author | Ugedo Urruela, Luisa | |
dc.contributor.author | De Deurwaerdère, Philippe | |
dc.date.accessioned | 2018-06-14T11:42:51Z | |
dc.date.available | 2018-06-14T11:42:51Z | |
dc.date.issued | 2017-09-12 | |
dc.identifier.citation | Frontiers in Cellular Neuroscience 11 : (2017) // Article ID 274 | es_ES |
dc.identifier.issn | 1662-5102 | |
dc.identifier.uri | http://hdl.handle.net/10810/27524 | |
dc.description.abstract | The link between the anti-Parkinsonian drug L-3,4-dihydroxyphenylalanine (L-DOPA) and the serotonergic (5-HT) system has been long established and has received increased attention during the last decade. Most studies have focused on the fact that L-DOPA can be transformed into dopamine (DA) and released from 5-HT terminals, which is especially important for the management of L-DOPA-induced dyskinesia. In patients, treatment using L-DOPA also impacts 5-HT neurotransmission; however, few studies have investigated the mechanisms of this effect. The purpose of this review is to summarize the electrophysiological and neurochemical data concerning the effects of L-DOPA on 5-HT cell function. This review will argue that L-DOPA disrupts the link between the electrical activity of 5-HT neurons and 5-HT release as well as that between 5-HT release and extracellular 5-HT levels. These effects are caused by the actions of L-DOPA and DA in 5-HT neurons, which affect 5-HT neurotransmission from the biosynthesis of 5-HT to the impairment of the 5-HT transporter. The interaction between L-DOPA and 5-HT transmission is especially relevant in those Parkinson's disease (PD) patients that suffer dyskinesia, comorbid anxiety or depression, since the efficacy of antidepressants or 5-HT compounds may be affected. | es_ES |
dc.description.sponsorship | The project was funded by grants from the Government of the Basque Country (IT 747-13), the Spanish Government [SAF2016-77758-R (AEI/FEDER, UE)] and by the Fondation de France. PDD acknowledges the support given by the cooperation for science and technology (COST) action CM15120. PDD and AB acknowledge the support of the Centre National de la Recherche Scientifique. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | serotonin | es_ES |
dc.subject | dopamine | es_ES |
dc.subject | electrophysiology | es_ES |
dc.subject | intracerebral microdialysis | es_ES |
dc.subject | depression | es_ES |
dc.subject | dyskinesia | es_ES |
dc.subject | Parkinson's disease | es_ES |
dc.subject | exocytosis | es_ES |
dc.subject | dorsal raphe nucleus | es_ES |
dc.subject | levodopa-induced dyskinesias | es_ES |
dc.subject | high-frequency stimulation | es_ES |
dc.subject | 5-ht4 receptors exert | es_ES |
dc.subject | in-vivo | es_ES |
dc.subject | extracellular dopamine | es_ES |
dc.subject | rat model | es_ES |
dc.subject | 6-hydroxydopamine-treated rats | es_ES |
dc.subject | nigrostriatal denervation | es_ES |
dc.title | Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | 2017 Miguelez, Benazzouz, Ugedo and De Deurwaerdère. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fncel.2017.00274/full | es_ES |
dc.identifier.doi | 10.3389/fncel.2017.00274 | |
dc.departamentoes | Farmacología | es_ES |
dc.departamentoeu | Farmakologia | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as 2017 Miguelez, Benazzouz, Ugedo and De Deurwaerdère. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.